Molecular Detection (MDI) and Integrated Sciences have entered into an agreement for the distribution of MDI's in-vitro diagnostic test, Detect-Ready MRSA (methicillin-resistant Staphylococcus aureus) assay in Australia.

The Detect-Ready MRSA kit is a qualitative real-time PCR (rt-PCR) in-vitro diagnostic test for the direct detection of MRSA nasal colonization to aid in the prevention and control of MRSA infections in hospitals and other healthcare settings.

The technology in the Detect-Ready kits provides a differential diagnosis engine that produces highly accurate results, minimizing the false positives and false negatives experienced with other MRSA screening kits.

The Detect-Ready kits are compatible with multiple rt-PCR platforms currently found in clinical laboratories, including the Roche LightCycler, Qiagen Rotor-Gene and Cepheid SmartCycler.

The flexibility to leverage existing infrastructure and equipment to run Detect-Ready assays eliminates the need for additional hospital capital investment.

The Detect-Ready MRSA assay kit has received the CE mark certification for sales in the European Union and is currently also available in Germany, the UK, Spain, Ireland, Switzerland, and Austria.

MDI CEO Todd Wallach said that this latest agreement continues their strategy of partnering their Detect-Ready MRSA assay with distributors worldwide and the Detect-Ready MRSA assay offers important advantages.

“We believe that Integrated Sciences’ focus on top-quality customer service and expert technical support, along with its national reach, will help their Detect-Ready assay achieve strong acceptance in the growing Australian market for MRSA screening,” Wallach said.